Jefferies LLC

UK legal finance firm Vannin Capital plans to go public in the autumn, having filed an intention to float document in London on Monday.

The UK’s RPC Group is in talks with two private equity firms for a potential sale, with the plastics packaging company’s pre-acquisition leverage well below covenant breaching levels.

The Asian follow-on and block markets saw two transactions in Chinese healthcare names this week that raised a total of $250m.

Chinese biotechnology firm Zai Lab is tapping equity investors for around $150m, hitting the market with a follow-on sale of American Depository Shares (ADS).

Tom Muoio is joining Fitch Ratings' corporate issuer team in September, three months after leaving Jefferies.

Jefferies has hired a three person team from HSBC to build out its UK M&A operations, including Philip Noblet, vice-chairman of global banking and former co-head of banking for the UK.

Glenveagh Properties, the Irish housing developer owned by Oaktree Capital, has concluded the final leg of its €213m placing, conditional placing and open offer, which it originally announced in July to finance the acquisition of more land in Ireland.

BMC Software was set to print $2bn of triple-C rated bonds this week, as it changes sponsor hands from Bain and Golden Gate to KKR. The new owner was also pushing for some of the loosest covenants in the market.

The funding for KKR’s acquisition of BMC Software is set to add almost $2bn of high yield bonds in euros and dollars this week, the last portion of a cross-border, multi-billion debt deal that has enlivened the leveraged finance markets.

Tritax has raised £300m through a fixed price IPO in order to create a new real estate investment trust focused on logistics property in continental Europe.

Bio-technology firms AOBiome Therapeutics and Stealth Biotherapeutics Corp are seeking the greenlight to float in Hong Kong, adding to a fast-growing pipeline from the sector.

Hong Kong’s new biotechnology-friendly listing regime attracted IPO filings this week from China-based Innovent Biologics and MicuRx Pharmaceuticals.